10-QPeriod: Q3 FY2025

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2025

Filed October 21, 2025For Securities:DGX

Summary

Quest Diagnostics reported solid financial performance for the nine months ended September 30, 2025, with net revenues increasing by 13.5% to $8.2 billion, driven significantly by acquisitions and organic growth within its Diagnostic Information Services (DIS) segment. Net income attributable to Quest Diagnostics grew by 15.0% to $747 million, and diluted earnings per share (EPS) rose by 14.5% to $6.57. The company generated substantial operating cash flow of $1.4 billion, reflecting improved operational efficiency and the positive impact of the CARES Act payroll tax credit. Strategic investments continue, including capital expenditures and the ongoing 'Invigorate' program aimed at cost savings and productivity improvements. While the company experienced increased interest expenses due to recent debt issuance and higher operating costs, including wages and supplies, these were largely offset by revenue growth and cost-saving initiatives. Management remains focused on navigating potential impacts from new healthcare legislation like the OBBBA and the expiration of enhanced premium tax credits, though current estimates suggest a minimal impact on near-term revenues. The company also actively managed its capital structure through debt repayments and share repurchases, demonstrating a commitment to shareholder returns and financial flexibility.

Financial Highlights

56 data points
Beta

Revenue

$2.82B

33.7% Gross Margin

Net Income

$245.00M

8.7% Net Margin

EPS (Diluted)

$2.16

Total Assets

$16.20B

Cash & Equivalents

$432.00M

Free Cash Flow

$419.00M

Financial Statements
Beta
Revenue$2.82B
Cost of Revenue$1.87B
Gross Profit$949.00M
SG&A Expenses$501.00M
Operating Expenses$2.43B
Operating Income$386.00M
Net Income$245.00M
EPS (Basic)$2.18
EPS (Diluted)$2.16
Shares Outstanding (Basic)112.00M
Shares Outstanding (Diluted)113.00M

Key Highlights

  • 1Net revenues increased by 13.5% to $8.2 billion for the nine months ended September 30, 2025, primarily driven by the DIS segment.
  • 2Net income attributable to Quest Diagnostics rose by 15.0% to $747 million for the nine months ended September 30, 2025.
  • 3Diluted earnings per share increased by 14.5% to $6.57 for the nine months ended September 30, 2025.
  • 4Net cash provided by operating activities was $1.4 billion for the nine months ended September 30, 2025, a significant increase from the prior year.
  • 5The company completed the acquisition of select clinical testing assets of Spectra Laboratories in August 2025.
  • 6The 'Invigorate' program continues to focus on driving cost savings and productivity improvements across the value chain.
  • 7The company repurchased $150 million of its common stock during the nine months ended September 30, 2025.

Frequently Asked Questions

Revenue growth was primarily driven by the Diagnostic Information Services (DIS) segment, fueled by both recent acquisitions (contributing approximately 8.9% to DIS revenue in the nine-month period) and organic growth. The increase in requisition volume, especially from acquisitions, and a modest rise in revenue per requisition on an organic basis also contributed significantly.

While the cost of services and SG&A expenses increased due to acquisitions, wage inflation, and higher supplies costs, the company implemented cost savings and productivity improvements through its 'Invigorate' program. Amortization expense also increased due to acquisitions. Net income growth indicates that revenue increases and cost management efforts were largely effective in offsetting these pressures.

Quest Diagnostics is assessing the impact of the One Big Beautiful Bill Act (OBBBA) and the expiration of enhanced premium tax credits. While current estimates suggest a minimal impact on consolidated revenues for 2025 and 2026, the company anticipates a potential reduction of up to 50-60 basis points by 2028 compared to 2025, primarily affecting ACA-related exchange plan revenues. The tax provisions of the OBBBA are not expected to materially impact the statement of operations.

Quest Diagnostics repaid $600 million of senior notes at maturity and repurchased $150 million of its common stock during the nine months ended September 30, 2025. The company also continued its quarterly cash dividend program, increasing the dividend to $0.80 per common share in 2025. Approximately $735.9 million remained available under its share repurchase authorization as of September 30, 2025.